ConductScience.org, home

Paper25755575

Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.

Gupta V and 6 others. J Clin Exp Hepatol, 2014. Cited by 6 papers, by iCite.

Cite this record

ConductScience Library. Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India. Papers, record 25755575. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/25755575

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Sustained virological response rates to antiviral therapy in genotype 1 and 3 chronic hepatitis C patients: a study from north India.
PubMed
Journal
J Clin Exp Hepatol
PubMed
Year
2014
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
6
iCite
Relative citation ratio, by iCite
0.21
iCite
Revised in PubMed
2020-10-01
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Gupta VVarun
2Kumar AAshish
3Sharma PPraveen
4Tyagi PPankaj
5Bansal NNaresh
6Singla VVikas
7Arora AAnil

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References21

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
115660393High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.Hepatology2005https://conductscience.org/library/papers/15660393PubMed
218184194Inferior response of Asian vs non-Asian hepatitis C genotype 3 infection to combination antiviral therapy.J Viral Hepat2008https://conductscience.org/library/papers/18184194PubMed
318715665Treatment predictors of a sustained virologic response in hepatitis B and C.J Hepatol2008https://conductscience.org/library/papers/18715665PubMed
414996676Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose.Ann Intern Med2004https://conductscience.org/library/papers/14996676PubMed
519330875Diagnosis, management, and treatment of hepatitis C: an update.Hepatology2009https://conductscience.org/library/papers/19330875PubMed
621706207Prediction of sustained virological response to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C.Dig Dis Sci2011https://conductscience.org/library/papers/21706207PubMed
711583749Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Lancet2001https://conductscience.org/library/papers/11583749PubMed
88849147Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group.Ann Intern Med1996https://conductscience.org/library/papers/8849147PubMed
920032543Optimal length of antiviral therapy in patients with hepatitis C virus genotypes 2 and 3: a meta-analysis.Antivir Ther2009https://conductscience.org/library/papers/20032543PubMed
1014996679Heterogeneous virologic response rates to interferon-based therapy in patients with chronic hepatitis C: who responds less well?Ann Intern Med2004https://conductscience.org/library/papers/14996679PubMed
1119024206Treatment and vaccination for hepatitis C: present and future.J Ayub Med Coll Abbottabad2008https://conductscience.org/library/papers/19024206PubMed
1215057741Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment.Gastroenterology2004https://conductscience.org/library/papers/15057741PubMed
1318834319Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.Clin Infect Dis2008https://conductscience.org/library/papers/18834319PubMed
1419152711A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients.BMC Gastroenterol2009https://conductscience.org/library/papers/19152711PubMed
1519084938Pegylated interferon plus ribavirin for genotype Ib chronic hepatitis C in Japan.World J Gastroenterol2008https://conductscience.org/library/papers/19084938PubMed
1612739994Pegylated interferon with ribavirin therapy for chronic infection with the hepatitis C virus.Expert Opin Pharmacother2003https://conductscience.org/library/papers/12739994PubMed
1719624082Management of HCV infection: current issues and future options.Trop Gastroenterol2009https://conductscience.org/library/papers/19624082PubMed
1817264426Pegylated interferon alfa 2b and oral ribavirin in patients with HCV-related cirrhosis.Indian J Gastroenterol2006https://conductscience.org/library/papers/17264426PubMed
1923675659Current and future therapies for hepatitis C virus infection.N Engl J Med2013https://conductscience.org/library/papers/23675659PubMed
2020838466A novel small molecule inhibitor of hepatitis C virus entry.PLoS Pathog2010https://conductscience.org/library/papers/20838466PubMed

See all 21 referencesDownload CSV of references

Cited by5

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 6 citations.

PMIDTitleJournalYearIn PapersSource
37303399End Treatment Response and Sustained Viral Response in Patients With Hepatitis C Virus Receiving Sofosbuvir and Daclatasvir.Cureus2023https://conductscience.org/library/papers/37303399PubMed
30903612Genotype distribution in relation to viral load in a large cohort of Indian patients with chronic hepatitis C virus infection: A retrospective analysis.Indian J Gastroenterol2019https://conductscience.org/library/papers/30903612PubMed
29168457Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India.Indian J Med Res2017https://conductscience.org/library/papers/29168457PubMed
27822881Efficacy and safety of sofosbuvir-based therapy for chronic hepatitis C infection in "real-life" cohort.Indian J Gastroenterol2016https://conductscience.org/library/papers/27822881PubMed
26898400Parallel expression profiling of hepatic and serum microRNA-122 associated with clinical features and treatment responses in chronic hepatitis C patients.Sci Rep2016https://conductscience.org/library/papers/26898400PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/25755575

GET https://conductscience.org/api/papers/v1/25755575/references?page=2